Flow cytometry has emerged as a cornerstone technology in clinical trials, providing unparalleled capabilities to probe in depth characteristics of single cells simultaneously through multiparametric analysis. Its application spans diverse clinical areas, including oncology, hematology, and autoimmune diseases. In recent years, advancements in flow cytometry—such as increased sensitivity, automation, and integration with computational analytics—have significantly expanded its role in clinical research. Flow cytometry is now essential for monitoring immune responses, detecting minimal residual disease (MRD), profiling disease biomarkers, and predicting or correlating clinical outcomes. These capabilities make it an indispensable tool for both drug development and the implementation of precision medicine in clinical trials.
Minimal Residual Disease Detection
The ability to detect very small numbers of cancer cells that remain in the body after treatment (minimal residual disease-MRD) is one of the most impactful clinical applications of flow cytometry, particularly in hematological malignancies such as leukemia and multiple myeloma. Next-generation flow cytometry assays offer high sensitivity and specificity, enabling the detection of rare malignant cells that persist after treatment.
Flow cytometry detects MRD by identifying and quantifying abnormal cells that persist after treatment, which are undetectable by standard morphological methods. At diagnosis, a patient’s malignant cells are characterized for their unique immunophenotype—distinct patterns of cell surface antigens known as leukemia-associated immunophenotypes —using panels of fluorescently labeled antibodies. After treatment, bone marrow or blood samples are periodically collected, stained with these antibody panels, and analyzed by flow cytometry. This technique can examine thousands to millions of cells, enabling sensitive detection of rare abnormal cells with the same immunophenotype as the original malignant clone, with modern multiparametric flow cytometry achieving sensitivities as high as 0.01% to 0.001% (one abnormal cell among 10,000 to 100,000 normal cells).
The ability to accurately quantify MRD provides critical prognostic information, supports therapeutic decision-making, and is increasingly used as a surrogate endpoint in clinical trials, potentially accelerating drug approval processes.
Immune Cell Profiling
Flow cytometry enables comprehensive immune cell profiling by simultaneously measuring multiple markers on individual cells. This allows for detailed characterization of immune cell subsets, functional states, and activation profiles. In clinical trials, immune profiling is vital for understanding patient heterogeneity, stratifying participants, and identifying responders versus non-responders to immunotherapies. High-dimensional immune profiling also facilitates biomarker discovery and the elucidation of disease mechanisms.
Immune cell profiling involves monitoring of immunological responses to therapies such as vaccines, checkpoint inhibitors, and CAR-T cells. For example, in cancer immunotherapy trials, flow cytometry is used to track changes in T cell subsets and activation or exhaustion markers (like PD-1 and CTLA-4) in blood and tumor samples, helping to correlate immune profiles with treatment outcomes and identify potential adverse events. Its ability to deliver rapid, multiparametric, and quantitative data makes flow cytometry an essential tool for evaluating immune responses in clinical research.
Disease Biomarkers
The identification and validation of disease biomarkers are central to translational medicine and drug discovery. Flow cytometry is used in clinical trials to study biomarkers because it enables rapid analysis of individual cells within complex populations. This technique allows researchers to simultaneously measure multiple biomarkers on or within single cells, providing detailed phenotypic and functional information about immune and other cell types. Flow cytometry is particularly valuable for monitoring immune responses to investigational drugs by assessing changes in cell surface markers, intracellular proteins, cytokine production, cell activation, and proliferation.
Additionally, flow cytometry can be used to evaluate pharmacodynamic and pharmacokinetic effects by measuring receptor occupancy, target engagement, and downstream signaling events at the single-cell level. For example, in clinical trials of immune checkpoint inhibitors like anti-PD-1 antibodies, flow cytometry is used to quantify the percentage of immune cells whose PD-1 receptors are occupied by the therapeutic antibody in patient blood samples. This information helps determine the optimal dose needed for maximal receptor blockade, correlates drug exposure with biological effect, and informs dosing regimens and patient selection. Overall, flow cytometry’s ability to provide rapid, high-content, single-cell data makes it an essential tool for biomarker analysis in modern clinical trials, supporting both exploratory research and critical decision-making.
Predicting and Correlating Flow Cytometry Data with Therapeutic Efficacy
Flow cytometry is increasingly used to predict and correlate therapeutic efficacy in clinical trials. By monitoring changes in immune cell populations, activation markers, serum markers, and MRD status, researchers can assess early responses to therapy and predict long-term outcomes.
Several methods can be used to assess, analyze, and integrate flow cytometry data in order to correlate markers with and predict therapeutic efficacy. Three ways are listed below.
- Assessment of pharmacodynamic (PD) responses: Flow cytometry can measure changes in cell populations, activation markers, receptor occupancy, and functional responses, providing early evidence of whether a therapeutic is engaging its intended target and eliciting the desired biological effect.
- Biomarker discovery and validation: By identifying and quantifying biomarkers associated with therapeutic response, flow cytometry helps select patients most likely to benefit from a treatment and facilitates patient stratification.
- Integration of pharmacokinetics (PK) and PD data: Flow cytometry data can be combined with PK analyses to model dose-response relationships, optimize dosing regimens, and predict therapeutic windows.
Monitoring Immune Responses
Monitoring immune responses is fundamental in trials including immunotherapies and vaccines. It offers a comprehensive view of the immune system during, and after intervention. Flow cytometry enables rapid, multiparametric analysis within complex populations. Researchers use it to characterize immune cell subsets, monitor changes in these populations, assess functional responses like cytokine production, and measure drug-target engagement.
For example, in cancer immunotherapy trials, flow cytometry is used to track changes in T cell populations, evaluate activation markers, and quantify receptor occupancy on T cells to determine the effectiveness of treatments like checkpoint inhibitors. Additionally, flow cytometry is widely applied in vaccine trials, autoimmune disease studies, and cell therapy trials to monitor immune responses and identify potential biomarkers. These capabilities make flow cytometry an essential tool for understanding immune mechanisms, guiding clinical decisions, and improving the design and outcomes of clinical trials.
Conclusion
Flow cytometry has become an indispensable tool in clinical trials, offering high-resolution insights into cellular and molecular processes that underpin disease and therapeutic response. Its applications in MRD detection, immune profiling, biomarker discovery, and efficacy monitoring are driving advances in precision medicine and accelerating the development of new therapies. As technology continues to evolve, the standardization and integration of flow cytometry into multicenter clinical trials will further enhance its impact, ultimately improving patient outcomes and the efficiency of drug development.
The Table below summarizes the role of flow cytometry in clinical trials, disease indications commonly studied, and specific cell types analyzed by flow cytometry in those contexts.
| Topic | Role in Clinical Trials | Example 1: Disease Indication & Cell Type | Example 2: Disease Indication & Cell Type |
|---|---|---|---|
| Minimal Residual Disease Detection | Detects rare malignant cells post-treatment to assess residual disease, inform prognosis, and serve as surrogate endpoints in trials | Acute Lymphoblastic Leukemia (ALL): B lymphoblasts | Multiple Myeloma: Plasma cells |
| Immune Cell Profiling | Characterizes immune cell subsets and functional states to stratify patients, identify responders, and discover biomarkers | Rheumatoid Arthritis: CD4+ T helper cells | Melanoma: Tumor-infiltrating lymphocytes (TILs) |
| Disease Biomarkers | Identifies and validates diagnostic, prognostic, and predictive markers to monitor disease and guide therapy | Chronic Lymphocytic Leukemia (CLL): CD19+ B cells | Systemic Lupus Erythematosus (SLE): CD27+ memory B cells |
| Predicting/Correlating with Therapeutic Efficacy | Monitors changes in cell populations and activation markers to predict and correlate treatment response and optimize regimens | Non-Hodgkin Lymphoma: CD8+ cytotoxic T cells | Psoriasis: Th17 (CD4+ IL-17+) cells |
| Monitoring Immune Responses | Tracks immune activation, suppression, and memory formation to assess vaccine or immunotherapy effects | COVID-19 Vaccine Trials: Memory CD8+ T cells | Melanoma Immunotherapy: Regulatory T cells (Tregs) |
Related blog: Flow cytometry in Developing Cell-Based Potency Assays for AAV Gene Therapies
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
